Unione Europea - italiano - EMA (European Medicines Agency)

ucb pharma s.a.   - bimekizumab - psoriasi - immunosoppressori - plaque psoriasisbimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisbimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - fingolimodum - capsule - fingolimodum 0,5 mg per fingolimodi hydrochloridum, mannitolum, magnesio stearas, kapselhülle: e 172 (giallo), e 171, gelatina, drucktinte: lacca, alcol isopropylicus, alcol butylicus, propylenglycolum, acqua purificata, ammoniae soluzione del 28 per cento, kalii hydroxidum, e 172 (nero), e 172 (giallo), e 171, dimeticonum per una piccola scatola. - multiple sklerose - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

novartis pharma schweiz ag - fingolimodum - capsule - fingolimodum 0.25 mg ut fingolimodi hydrochloridum, mannitolum, hydroxypropylcellulosum, hydroxypropylbetadexum, magnesii stearas, kapselhülle: gelatina, e 171, e 172 (flavum), drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammoniae solutio 28 per centum pro capsula. - multiple sklerose - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - fingolimodum - capsule - fingolimodum 0.5 mg ut fingolimodi hydrochloridum, amylum pregelificatum, natrii laurilsulfas corresp. natrium 0.045 mg, kapselhülle: e 171, e 172 (flavum), gelatina, drucktinte: lacca, propylenglycolum, ammoniae solutio concentrata, e 172 (nigrum), kalii hydroxidum, pro capsula. - multiple sklerose - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

viatris pharma gmbh - fingolimodum - capsule rigide - fingolimodum 0.5 mg ut fingolimodi hydrochloridum, calcii hydrogenophosphas dihydricus, glycinum, silica colloidalis anhydrica, magnesii stearas, kapselhülle: e 171, gelatina, e 172 (rubrum), e 172 (flavum), drucktinte: lacca, propylenglycolum, e 172 (nigrum), kalii hydroxidum, pro capsula. - multiple sklerose - synthetika

Unione Europea - italiano - EMA (European Medicines Agency)

hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - immunosoppressori - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.

Unione Europea - italiano - EMA (European Medicines Agency)

takeda pharma a/s - vedolizumab - colitis, ulcerative; crohn disease - immunosoppressori selettivi - la colite colitisentyvio è indicato per il trattamento di pazienti adulti con moderatamente a gravemente attiva la colite ulcerosa, che hanno avuto una risposta inadeguata, persa la risposta, o sono intolleranti a terapia convenzionale o fattore di necrosi tumorale alfa (tnfa) antagonista. il morbo di crohn diseaseentyvio è indicato per il trattamento di pazienti adulti con moderata a grave malattia di crohn attiva che hanno avuto una risposta inadeguata, persa la risposta, o sono intolleranti a terapia convenzionale o fattore di necrosi tumorale alfa (tnfa) antagonista. pouchitisentyvio is indicated for the treatment of adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis, and have had an inadequate response with or lost response to antibiotic therapy.

Unione Europea - italiano - EMA (European Medicines Agency)

mylan ireland limited - dimetilfumarato - sclerosi multipla recidivante-remittente - immunosoppressori - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Unione Europea - italiano - EMA (European Medicines Agency)

zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - dimetilfumarato - sclerosi multipla recidivante-remittente - immunosoppressori - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Unione Europea - italiano - EMA (European Medicines Agency)

teva gmbh - dimetilfumarato - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosoppressori - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).